From July 27 to 29, the "2023 Shenzhen International Biomedical Industry Innovation and Development Conference" jointly sponsored by Shenzhen Municipal People's Government as the guiding unit, Shenzhen Municipal Development and Reform Commission, Shenzhen Municipal Science and Technology Innovation Commission, Shenzhen Pingshan District People's Government, and Shenzhen Dapeng New District Management Committee was held in Shenzhen Pingshan Yanzi Lake International Convention and Exhibition Center. With the theme of "Cross-border integration, deep into the future", the conference set up a closed-door meeting of pharmaceutical leaders, a keynote forum and 9 professional theme forums, focusing on the "tuyre" of innovative medical devices, emerging biological drugs and other industries and the business service needs of enterprises going abroad and internationalization, investment and financing, creating a high-standard, high-standard and high-level international biomedical industry event.

The conference invited 13 famous Chinese and foreign academicians from China, the United States, Russia, Canada, Europe and other countries, presidents of 5 major IT giants, more than 20 former FDA experts, As well as deans and professors of many academic medical institutions such as Shenzhen Third People's Hospital, Johns Hopkins University, Peking University School of Pharmacy, Southern University of Science and Technology Biomedical Research Institute, Shenzhen University of Technology School of Pharmacy. Experts in various fields analyze industry trends, insight into the technological frontier, lead innovation investment, and offer suggestions for the development of Shenzhen's biological industry.

In the innovative Biologic medicine Forum, Dr. Shi Yuanyuan, chairman of the board, delivered a wonderful speech entitled "Cell therapy and the Development Prospect of the Big health Industry". Dr. Shi Yuanyuan said that under the combined effect of market, policy and investment, China's large health industry has entered a period of rapid growth, and the fields of health management, specialized medical treatment, health maintenance, biomedics and other fields have developed rapidly. Clinical research and application of cell therapy are not only the most concerned subdivisions of the cell medical industry, but also have become one of the hottest research fields in today's biomedics. And plays an important role in a growing number of disease areas.

Dr. Shi Yuanyuan pointed out that with the increasing incidence of cancer in China year by year, cell therapy, as the fourth therapy of chemotherapeutics, targeted drugs and antibody drugs, has shown absolute advantages in the treatment of hematoma, and has been highly valued by the national and local governments, which has effectively promoted the transformation of the cell medical industry from cell storage to applied research. With the release of relevant legal standards for cell clinical therapy, China has gradually entered an era of comprehensive and orderly development of cell clinical therapy, which is bound to have an important impact on the national medical health system and lead a new round of treatment revolution. Shenzhen Cell Valley has the only retroviral vector GMP industrial production line in China, and is committed to creating a "one-stop cell and gene therapy CRO/CDMO service platform". For the pharmaceutical companies engaged in cell and gene therapy, hospitals, research institutes and other institutions to provide instruments and equipment, reagents consumables, early research and development, clinical research, commissioned production to new drug IND declaration, NDA declaration on the upper, middle and downstream chain services, while training for the country and the industry in the field of cell and gene therapy in short supply of a large number of professional and technical personnel. Shenzhen is committed to building a biomedical industry highland, and Shenzhen Cell Valley will make full use of its own advantages to contribute to the high-quality development of the biomedical industry.